{
    "nctId": "NCT01610050",
    "briefTitle": "A Phase I Study of LFA102 in Japanese Patients",
    "officialTitle": "A Phase I, Multicenter, Open-label Study of LFA102 Administered Intravenously in Japanese Patients With Castration-resistant Prostate Cancer or Advanced Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Castration-resistant Prostate Cancer, Advanced Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1",
    "allocation": "NON_RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 14,
    "primaryOutcomeMeasure": "Dose Limiting Toxicities (DLT)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Histologically confirmed diagnosis of prostate cancer\n* Histologically or cytologically confirmed locally advanced or metastatic breast cancer\n\nExclusion Criteria:\n\n* Patients with untreated and/or symptomatic metastatic CNS disease\n* Prior anaphylactic or other severe infusion reaction\n* Treatment with agent which affect prolactin levels\n* Active autoimmune disease\n\nOther protcol-defined Inclusion/Exclusion criteria may apply.",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}